The impact of Novo Nordisk's weight loss injections on the economy is controversial among experts as they could potentially influence purchasing behavior and sales in various industries.

The impact of Novo Nordisk's weight loss injections on the economy is controversial among experts as they could potentially influence purchasing behavior and sales in various industries.

According to a report by www.tagesschau.de,

The slimming syringes from the pharmaceutical company Novo Nordisk, such as Ozempic and Wegovy, are particularly popular in the USA. The substance it contains, semaglutide, originally developed to treat type 2 diabetes, has an appetite-suppressing effect. This has an impact on various sectors of the economy. The US supermarket chain Walmart is already observing a change in shopping behavior among customers who use these medications. This led to price losses for Walmart and international brands such as Lindt & Sprüngli, Nestlé and Kellanova.

The investment bank Barclays predicts sales declines at food companies due to weight loss injections of more than one percent. Manufacturers of alcoholic beverages could even suffer sales losses of up to three percent. German confectionery manufacturers have so far been relatively untouched. The syringes are in high demand in the USA, while the “hype” in Germany has so far been low because the syringes are expensive and require a prescription.

Demand is expected to increase worldwide. Companies that cater to overweight patients will face competition from weight loss injections. Another possible effect is the reduction of dialysis treatments for kidney patients, which could affect the dialysis provider Fresenius Medical Care. The weight loss injections could also have an impact on the textile industry and airlines, as changes in body weight could mean additional sales or savings.